Replies to post #267111 on Avid Bioservices Inc (CDMO)

[Protector]

Habitual, thanks. I am confused. This article is from 22 JUN 2016 (today) yet Gabrilovich gives yet another description of the clinical trials of peregrine Pharmaceuticals (PPHM).

Development efforts, however, are continuing on several fronts. A phase II study is currently being designed to assess the PD-L1 inhibitor durvalumab with or without bavituximab for patients with previously treated metastatic NSCLC. This trial was initiated in February 2016 and has not yet started to recruit patients (NCT02673814).

Additionally, a phase II study of neoadjuvant bavituximab in combination with paclitaxel in patients with early-stage triple-negative breast cancer is planned (NCT02685306).

Gabrilovich is involved in several clinical studies focused on MDSC strategies, although he did not want to discuss the details of those efforts. Wistar is a National Cancer Institute–designated cancer centre devoted to basic research that helps translate discoveries through partnerships with academic medical centres and biopharmaceutical companies.

source

1) PPHM said they would stop/not start any PII/PIII clinical trials.
2) PPHM said NSCLC was crowded and the enrolment part doesn't match the ASCO 2016 text.
3) Paclitaxel is a CHEMO, but OK it is Breast Cancer were chemo is still king.
4) The trial that will be started Durvalumab+Bavi in solid cancers is not there.

It is troubling that we keep getting contradictive information from PPHM web-site, PPHM publications, PPHM PR and now PPHM KOL's. But ok, communication is PPHM's weak point, even after the CA has been dismissed :)

Of course maybe PPHM is confusing the cat!

[north40000]

I would like to know the identity of the 20 companies that sponsored/attended that 4-day conference, besides PPHM and Reata?.